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cations of hypertension such as stroke have decreased. 
However, the occurrence of cardiovascular organ fail-
ures such as end stage renal disease and cardiac fail-
ure continues to increase. Regarding the animal model 
of hypertensive organ injuries, the development of 
nephrosclerosis is not obvious until much later stage of 
life in spontaneously hypertensive rats （SHR）1）. In this 
respect, we have previously reported that SHR given 
N-nitro-L-arginine methyl ester （L-NAME）, a nitric 
????????????
With the use of antihypertensive therapy, the mor-
bidity and mortality from major cardiovascular compli-
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This study was designed to evaluate the protective effects of efonidipine, an L- and T-type calcium chan-
nel blocker, against hypertensive renal injuries in spontaneously hypertensive rats （SHR） chronically treat-
ed with N-nitro-L-arginine methyl ester （L-NAME）, a nitric oxide synthase inhibiter. Four groups of sev-
enteen-week-old male SHR were treated for as follows：the control group, the L-NAME group given 
80 mg/L L-NAME in drinking water, and the groups given 5 （low-dose） or 20 （high-dose） mg/kg/day efo-
nidipine by gavage as well as 80 mg/L L-NAME in drinking. After three weeks, the rats were sacrificed 
and the degrees of renal injuries were compared. The L-NAME group developed renal dysfunction and re-
nal tissue lesions such as glomerulosclerosis, arterial wall thickening and perivascular fibrosis and cell infil-
tration with the aggravation of hypertension. The high-dose efonidipine improved the renal function and al-
leviated the renal tissue lesions in SHR given L-NAME as well as lowering blood pressure. On the other 
hand, the low-dose efonidipine also exhibited such renoprotective effects without causing significant chang-
es of blood pressure in L-NAME-treated SHR. Renal cortical mRNA expressions of transforming growth 
factor-b 1 （TGF-b 1） and peroxisome proliferator-activated receptor-g  （PPAR-g） were increased and de-
creased, respectively, in SHR given L-NAME. Such changes in the mRNA expressions were mitigated by 
either the low-dose or the high-dose efonidipine treatment. It is suggested that efonidipine is effective in in-
hibiting the progression of hypertensive renal injuries and the renoprotective effects are mediated by the 
mechanism independent of blood pressure reduction as well as by the antihypertensive action.
　???? ????： hypertension, nephrosclerosis, calcium channel blockers, transforming growth factor-beta, 
peroxisome proliferator-activated receptors
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blood pressure was measured by the tail-cuff method, 
and the treatment was continued for three weeks. Dur-
ing the final week of treatment, all rats were placed in 
metabolic cages for 2 days to collect 24-hour urine 
samples. 
After three weeks, the rats were sacrificed under 
pentobarbital anesthesia （30 mg/kg, intraperitoneally）. 
The kidneys were perfused and fixed with saline and 
neutral-buffered 8％ paraformaldehyde solution. Then, 
the left cardiac ventricle, thoracic aorta and the kid-
neys were excised, weighed and served for the prepa-
rations of histological examination. Plasma and urinary 
concentrations of creatinine and protein were assayed 
by colorimetry and urinary nitric oxides （NOx） were 
determined by high performance liquid chromatogra-
phy.
The kidneys were embedded in paraffin, and 2-mm 
frontal sections were cut for light microscopic histolog-
ical examination. These sections were stained with he-
matoxylin-eosin, periodic acid-Schiff （PAS） and Mas-
son trichrome for the assessment of glomerular and 
vascular injuries and perivascular lesions such as fibro-
sis and cell infiltration. Glomerular lesions were evalu-
ated in the juxtamedullary cortex, because juxtamed-
ullary glomeruli are more vulnerable to sclerosis than 
glomeruli in the superficial layer of cortex. The glom-
erular injury score （GIS） was assessed as described 
previously 4〜7）. In order to calculate GIS, the glomeru-
lar injury was graded from 0 to 3＋, in which 0 was no 
injury, 1＋ was injury up to one third of the glomeru-
lus, 2＋ was one third to two thirds glomerular injury, 
and 3＋ was injury of more than two thirds. Every 
glomeruli in the juxtamedullary layer of frontal section, 
generally 100 to 150 glomeruli, were evaluated in each 
rat and the scores were summed up. GIS was defined 
as the converted value of total score per 100 glomeruli. 
Namely, global sclerosis of every glomerulus corre-
sponds to the maximum GIS of 300. The wall thickness 
was assessed as the ratio of media thickness to the 
outer radius of interlobular arteries. Inner and outer 
circumferences were measured by the computer ana-
lyzer system （Image Quest, Hamamatsu Photonics, 
Hamamatsu and MacScope, Mitani Co., Fukui, Japan）. 
The values were corrected to the radius of each ves-
sel, which were assumed to be circular, by the follow-
ing calculation：wall thickness ratio＝（R-r）/R, where 
oxide synthase （NOS） inhibitor, develop marked pro-
teinuria and progressive hypertensive nephrosclero-
sis 2）. In addition, we observed that renin-angiotensin-
aldosterone system （RAAS） is markedly enhanced in 
this L-NAME-treated SHR and reported that the in-
hibitors of RAAS such as angiotensin-converting en-
zyme （ACE） inhibitors and b-blockers are effective in 
alleviating the development of nephroscrelotic le-
sions 3, 4）. 
In the process of hypertensive cardiovascular organ 
injuries, fibrotic and inflammatory tissue lesions devel-
op along with proliferation and hypertrophy of the 
cells. In this respect, transforming growth factor-b 1 
（TGF-b 1） is a profibrotic cytokine and peroxisome 
proliferator-activated receptor-g  （PPAR-g） has been 
shown to exhibit anti-inflammatory, anti-fibrotic and 
anti-hypertrophic effects on the cardiovascular tissues. 
Therefore, the changes in these factors seem intrigu-
ing in the treatment of hypertension targeting the pre-
vention of cardiovascular organ injuries. 
Calcium channel blockers are widely used in the 
treatment of hypertension and other cardiovascular 
diseases. In this study, we investigated the therapeutic 
effects of a dihydropyridine calcium channel blocker, 
efonidipine, on the progression of hypertension and 
nephrosclerosis in relation to the expressions of TGF-
b 1 and PPAR-g  in L-NAME-treated SHR.
???????
Male seventeen-week-old SHR （Charles River Labo-
ratories, Tokyo） with body weight of 290 to 330 g 
were used in this study and they were maintained on 
a regular chow containing 0.3％ NaCl. The experimen-
tal design was approved by the institutional animal 
care committee. The rats were divided into four ex-
perimental groups：group 1 rats （control, n＝15） were 
given tap water；group 2 rats （L-NAME, n＝14） 
were given 80 mg/L L-NAME （Sigma Chemical Co., 
St. Louis, USA） in their drinking water；group 3 rats 
（L-EFN, n＝10） were given 80mg/L L-NAME as 
drinking and administered low-dose （5 mg/kg/day） 
efonidipine, a calcium channel blocker, by gavage；
group 4 rats （H-EFN, n＝11） were given 80 mg/L L-
NAME as drinking and administered high-dose 
（20 mg/kg/day） efonidipine. Efonidipine was provided 
by ZERIA Pharmaceutiocal Co., Ltd., Tokyo. Systolic 
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R is the radius of the outer circumference and r is the 
radius of the inner circumference, and R-r represents 
medial thickness 4, 8）. The perivascular fibrosis area of 
interlobular artery was assessed by calculating the ra-
tio of the collagen-stained area to the vascular wall 
and lumen area in the section stained with Masson 
trichrome. The infiltrating cell number was assessed 
by counting the number of filtrating cells such as lym-
phocytic cells, plasma cells, fibroblasts and macrophag-
es in the perivascular space of interlobular artery us-
ing the Image Quest.
The total RNA of specimens was extracted from the 
renal cortical tissue using TRIzol reagent （Life Tech-
nologies, Rockville, Maryland, USA） according to the 
manufacturer’s procedure. The first-strand cDNA was 
made from the total RNA using the SuperScript pre-
amplification system （Life Technologies） with random 
hexamers. Excess oligomers were removed using a 
centrifugal filter, Microcon YM-10 （Millipore Co., Bed-
ford, Massachusetts, USA）. Real-time PCR analysis, 
using the ABI Prism 7700 Sequence Detection System 
（Perkin Elmer Applied Biosystems, Foster City, Cali-
fornia, USA）, is a method that provides reproducible 
quantitative PCR 9）. Cleavage of the sequence-specific 
probe （TaqMan Probe） by 5’ nuclease activity of the 
TaqDNA polymerase releases the reporter dye, result-
ing in an increase in emission at the corresponding 
wavelengths. With each cycle, the fluorescence intensi-
ty of additional reporter dye molecules is monitored by 
the system. Threshold cycles were selected in the line 
in which all samples were in logarithmic phase. The 
quantity of PCR products was calculated from the 
threshold cycle value. This real-time detection gener-
ates quantitative data based on PCR at early cycles 
when PCR fidelity is highest. TGF-b 1 and PPAR-g  
RNA levels were quantified as the ratios to b-actin us-
ing this real-time PCR system. All oligonucleotides 
were obtained by chemical synthesis using the PerSep-
tive 8900 （PE Biosystem, California, USA）. TaqMan 
probe which was modified with the fluorescent （pur-
chased from GRENER JAPAN, Inc., Tokyo, Japan）. 
The nucleotide sequences of the PCR primers and 
TaqMan probes were as follows：
TGF-b 1, 
　forward primer：5’-cgcctgcagagattcaagtcaa-3’
　reverse promer：5’-gtcggttcatgtcatggatggt-3’
　TaqMan probe： 5 ’-agtggctgaaccaaggagacggaata-
ca-3’
PPAR-g , 
　forward primer： 5’-cttggccatatttatagctgtcattatt-3’
　reverse promer：5’-agcaggttgtcttggatgtcct-3’
　TaqMan probe：5’-tggagaccgcccaggcttgct-3’
b-actin,
　forward primer：5’-cgtgaaaagatgacccagatca-3’
　reverse promer：5’-acacagcctggatggctacgta-3’
　TaqMan probe： 5’-tttgagaccttcaacaccccagcca-3’
One-way ANOVA, followed by Duncan’s multiple 
range test, was performed to test for between-group 
significance. All data are expressed as the mean±
SEM. A probability level of＜5％ was considered to 
indicate statistical significance.
???????
Table 1 lists the data of physical measurements and 
organ weights in the four groups of rats in this study. 
The L-NAME group developed marked hypertension 
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???????　Body weight, blood pressure and organ weights of rats at the end of 3-week treatment period.
Indices
Control
（n＝15） 
L-NAME
（n＝14）
L-EFN
＋L-NAME
（n＝10）
H-EFN
＋L-NAME
（n＝11）
Body weight, g 351±8 287±10＊＊ 303±11 318±9†
Systolic blood pressure, mmHg 233±4 271±8＊＊ 258±10 175±12††
Heart rate, bpm 459±15 441±32 470±18 466±13
Right kidney weight, g/kgBW   3.5±0.1   3.6±0.1   3.1±0.3   3.4±0.2
Left kidney weight, g/kgBW   3.7±0.1   3.7±0.1   3.6±0.2   3.9±0.1
Left ventricular weight, g/kgBW   3.2±0.1   3.7±0.1＊   4.4±0.2†   3.6±0.2
Data are mean±SEM. BW：body weight. ＊p＜0.05, ＊＊p＜0.01 vs. control；†p＜0.05, ††p＜0.01 vs. 
L-NAME. 
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and reduced body weight as compared with the con-
trol SHR group. The high-dose efonidipine alleviated 
this aggravation of blood pressure elevation and body 
weight reduction, while the low-dose efonidipine did 
not significantly affect the blood pressure and body 
weight of L-NAME-treated SHR. The kidney weight 
was not significantly affected by administration of ei-
ther L-NAME or efonidipine. The L-NAME treatment 
increased the cardiac left ventricular weight of SHR. 
The low-dose efonidipine increased but the high-dose 
efonidipine did not significantly changed the left ven-
tricular weight of L-NAME-treated SHR. 
Table 2 presents the results of chemical measure-
ments of plasma and urine samples. As compared with 
the control SHR, the plasma creatinine concentration 
was increased in the L-NAME group, however, the in-
creases were mitigated in the L-EFN and the H-EFN 
groups. The creatinine clearance was also markedly 
lower in the L-NAME group than in the control group, 
and either the low-dose or the high-dose efonidipine 
increased the creatinine clearance of L-NAME-treated 
SHR. The L-NAME group showed marked proteinuria 
as compared with the control group, however, this was 
significantly reduced in the L-EFN and the H-EFN 
groups. Regarding the urinary metabolites of nitric ox-
ides, the L-NAME treatment markedly reduced the 
urinary NOx excretion in SHR and either the low-dose 
or the high-dose efonidipine did not significantly affect 
the urinary NOx excretion in L-NAME-treated SHR. 
Figure 1 presents the representative micrographs of 
glomeruli in each group. The L-NAME-treated SHR 
showed marked sclerosis and hyalinosis of glomeruli, 
while the glomerular lesions were minimal in the con-
trol SHR （Figure 1, panels A and B）. Such glomerular 
sclerosis was much improved in the L-EFN or the H-
EFN groups （Figure 1, panels C and D）. The results 
of histological analyses were presented in Table 3. The 
L-NAME treatment markedly increased the GIS in 
SHR, however, this was prominently improved in the 
L-EFN or the H-EFN group. Figure 2 presents the 
micrographs of interlobular arteries. The L-NAME 
group showed the increased wall thickness ratio of in-
terlobular artery as compared with the control group 
（Figure 2, panels A and B）. and the increase was in-
hibited by either the low-dose or the high-dose efonid-
ipine treatment （Figure 2, panels C and D）. Both the 
fibrosis area and the number of infiltrating cells in the 
perivascular area of interlobular artery were increased 
in the L-NAME group as compared with the control 
group （Figure 2, panels A and B）. and these increases 
were suppressed in the L-EFN or the H-EFN group 
（Figure 2, panels C and D）. 
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???????　Chemical measurements of plasma and urine samples.
Indices
Control
（n＝15）
L-NAME
（n＝14）
L-EFN
＋L-NAME
（n＝10）
H-EFN
＋L-NAME
（n＝11）
Serum creatinine, mg/dL 0.20±0.02 0.51±0.06＊＊ 0.33±0.01†† 0.30±0.02††
C-Cr, mL/min/kg  9.5±1.0  3.3±0.1＊＊  5.4±0.6†  7.4±0.4††
Urinary protein, mg/day   19±1   120±13＊＊   69±19†    24±3††
Urinary NOx, µmol/day  5.0±0.5  0.6±0.2＊＊  1.1±0.2  1.3±0.3
Data are mean±SEM. C-Cr, creatinine clearance. ＊p＜0.05, ＊＊p＜0.01 vs. control；†p＜0.05, 
††p＜0.01 vs. L-NAME. 
???????　Histological findings of the kidneys of rats at the end of 3-week treatment period.
Indices
Control
（n＝15）
L-NAME
（n＝14）
L-EFN
＋L-NAME
（n＝10）
H-EFN
＋L-NAME
（n＝11）
Glomerular injury score     9±2   197±15＊＊    30±5††    18±4††
Wall thickness ratio 0.48±0.03 0.58±0.03＊ 0.47±0.02† 0.40±0.03††
Perivascular fibrosis area 0.35±0.04 0.91±0.11＊＊ 0.36±0.02†† 0.37±0.08††
Perivascular cell number number/104 mm2    47±7   110±10＊＊    47±3††    50±7††
Data are mean±SEM. ＊p＜0.05, ＊＊p＜0.01 vs. control；†p＜0.05, ††p＜0.01 vs. L-NAME. 
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????????　 Representative PAS-staining micrographs of glomeruli in each group. A：SHR 
without L-NAME or efonidipine, B：L-NAME-treated SHR, C：SHR given 
L-NAME and low-dose （5 mg/kg） efonidipine, D：SHR given L-NAME and 
high-dose （20 mg/kg） efonidipine. 
A
C
B
D
????????　 Representative Masson trichrome-staining micrographs of interlobular arteries 
and perivascular areas in each group. A：SHR without L-NAME or efonidipine, 
B：L-NAME-treated SHR, C：SHR given L-NAME and low-dose （5 mg/kg） 
efonidipine, D：SHR given L-NAME and high-dose （20 mg/kg） efonidipine. 
A
C
B
D
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Figure 3 depicts the mRNA expressions of TGF-b 1 
and PPAR-g  in the renal cortical tissues of rats quanti-
fied by the real-time PCR analyses. As we have previ-
ously reported, the TGF-b 1 mRNA expression in the 
kidney was markedly increased in L-NAME-treated 
SHR 3, 10）, however, the expression was suppressed in 
the L-EFN or the H-EFN group of this study. On the 
other hand, the mRNA expression of PPAR-g  in the 
kidney was reduced in the L-NAME group as com-
pared with the control group, and this reduction was 
significantly alleviated by either the low-dose or the 
high-dose efonidipine treatment. 
??????????
Hypertension is a major risk factor for cardiovascu-
lar organ injuries. In addition, cardiovascular risk fac-
tors such as aging, dyslipidemia and oxidative stress 
cause endothelial dysfunction and decreased NO pro-
duction which further promote cardiovascular tissue 
injuries. SHR treated with L-NAME, a NOS inhibitor, 
have been shown to develop hypertensive target organ 
injuries 2, 11）. With regard to the hypertensive renal in-
jury, we have previously reported the progression of 
glomerulosclerosis and vascular lesions in the kidneys 
of SHR given L-NAME with aggravation of hyperten-
sion 2）, while such renal lesions cannot be seen until 
much later stage of life in SHR without L-NAME 
treatment. Thus, it is assumed that L-NAME-treated 
SHR can serve as an experimental animal model of hy-
pertensive nephrosclerosis. In the present study, we 
examined the protective effects of a calcium channel 
blocker, efonidipine, against the progression of hyper-
tensive renal injuries in L-NAME-treated SHR. 
Either the low-dose or the high-dose efonidipine 
was effective in alleviating the renal dysfunction and 
renal tissue injuries such as glomerulosclerosis and 
vascular lesions. L-NAME-treated SHR develop 
marked hypertension and the high-dose efonidipine 
significantly lowered the blood pressure. Although the 
low-dose efonidipine failed to alter the blood pressure 
in L-NAME-treated SHR, the insignificant blood pres-
sure reduction may have related to the renoprotective 
effects. In addition, the effects such as suppression of 
TGF-b 1 and induction of PPAR-g  may have partici-
pated to the alleviation of hypertensive renal injuries. 
We have reported that L-NAME-treated SHR devel-
ops hypertensive nephrosclerosis with marked en-
hancement of RAAS 8）. According to the hyperfiltra-
tion theory, increases in glomerular capillary pressure, 
referred to as glomerular hypertension, play an impor-
tant role in the progression of renal dysfunction 12, 13）. 
Intraglomerular capillary pressure is affected by the 
tone of the glomerular arterioles as well as by the level 
of systemic arterial pressure. Because angiotensin II is 
a potent constrictor of the efferent arterioles, inhibitors 
of RAAS, which block the generation and/or action of 
angiotensin II, are thought to be effective at alleviating 
glomerular hypertension in L-NAME-treated SHR 14）. 
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????????　 Levels of mRNA for transforming growth factor-b 1 （TGF-b 1） and, peroxisome proliferation-
activated receptor-g  （PPAR-g） in the renal cortical tissues. ＊p＜0.05, ＊＊p＜0.01 vs. control；
†p＜0.05 vs. L-NAME. L-NAME, N-nitro-L-arginine methyl ester；L-EFN, low-dose 
efonidipine （5 mg/kg/day）；H-EFN, high-dose efonidipine （20 mg/kg/day）. 
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Indeed, we have reported that RAAS inhibitors such 
as ACE inhibitors and angiotensin II receptor blockers 
improve nephrosclerosis exacerbated by L-NAME in 
SHR 3, 10, 15, 16）. By contrast, calcium channel blockers 
tend to dilate the afferent arterioles and therefore are 
less effective at reducing intraglomerular pressure, 
when compared with specific inhibitors of the 
RAAS 17）. In this respect, it has been demonstrated 
that the glomerular efferent arterioles express the T-
type calcium channels. Efonidipine, used in this study, 
blocks the T-type calcium channels in addition to the 
L-type channels 18）, and efonidipine has been shown to 
dilate the efferent arterioles as well as the afferent ar-
terioles in the experiment using isolated perfused kid-
ney 19）. Also in the clinical study, we have reported 
that efonidipine reduced proteinuria in patients with 
nondiabetic renal diseases 20） and this may be related 
to a reduction in glomerular capillary pressure caused 
by the efferent arteriole dilation. Therefore, such ef-
fects of efonidipine on the glomerular hemodynamics 
may have contributed to the renoprotective effects ob-
served in this study. 
The mRNA expression of TGF-b 1 was increased by 
L-NAME treatment in SHR, and the increase was in-
hibited by the low-dose and the high-dose efonidipine. 
Because both angiotensin II and aldosterone have been 
shown to increase TGF-b 1 generation, the increased 
renal cortical TGF-b 1 expression in L-NAME-treated 
SHR is supposed to have been caused by the enhanced 
RAAS 21, 22）. TGF-b 1 is a cytokine which inhibits the 
immigration and proliferation of vascular cells on one 
side. On the other side, TGF-b 1 increases the produc-
tion of extracellular matrices and promotes the fibrosis 
of cardiovascular and renal tissues 23, 24）. On the other 
hand, the mRNA expression of PPAR-g  was decreased 
in L-NAME-treated SHR as compared with SHR, and 
the decrease was alleviated by the low-dose and the 
high-dose efonidipine. PPAR-g  has been shown to ex-
hibit anti-inflammatory, anti-fibrotic actions and anti-
hypertrophic effects on the cardiovascular tissues 25, 26）. 
The ligands of PPAR-g , such as pioglitazone, have 
been shown to exhibit blood pressure-lowering action 
by blockade of calcium uptake by vascular smooth 
muscle and antiproteinuric effect by increasing the 
gene transcription of nephrin 27, 28）. Thus, it is suggested 
that the inhibition of TGF-b 1 expression and the resto-
ration of PPAR-g  expression have participated in the 
renoprotective actions of efonidipine in L-NAME-
treated SHR. 
The left ventricular weight was increased by the L-
NAME treatment in SHR, however, the weight was 
unchanged by the high-dose efonidipine and was rath-
er increased by the low-dose efonidioine. We have pre-
viously shown that the necrotic and fibrotic lesions de-
velop in the cardiac tissue of L-NAME-treated 
SHR 11, 29）. Although the histological evaluation of cardi-
ac tissue was not performed in this study, a reduction 
of such changes may have resulted in the increase of 
left ventricular weight in the L-NAME-treated SHR 
given low-dose efonidipine. 
In conclusion, efonidipine may effectively inhibit the 
progression of hypertensive renal injuries. This reno-
protective effects are thought to be brought about by 
its antihypertensive effect. In addition, the mechanism 
such as TGF-b 1 suppression and PPAR-g  restoration 
may partly participate to the protective effects of efo-
nidipine against hypertensive renal injuries. 
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